

# Medmen Enterprises Inc.

11:21 12 Dec 2019

## Buds & Duds: Cannabis stocks higher on Thursday as troubled retailer MedMen reveals new round of layoffs

Cannabis indices were up on Thursday as a major multistate operator announced a further round of layoffs in North America.

The North American Marijuana Index, which tracks the top cannabis stocks in the US and Canada, was 1.3% higher to 112.8 points. Elsewhere, the Horizons Marijuana Life Sciences Index ETF rose 0.4% at C\$9.06, while the OTCQX Cannabis index gained 0.6% to 428.6 points.

### Buds

After a corporate update released on Wednesday evening that saw the firm laying off another 20% of its employees, pot retailer MedMen Enterprises Inc (CSE:MMEN) skyrocketed 12.3% in Canada and 9.5% over the counter in the US.

The California-based firm also announced some new financing that will result in US\$37 million in new proceeds, according to a release.

Shares of MedMen traded at C\$0.63 and US\$0.48 on Thursday morning.

1933 Industries Inc (CSE:TGIF) (OTCMKTS:TGIFF) saw its shares up on Thursday's news that it has signed a second licensing agreement with OG DNA Genetics, a globally recognized leading cannabis brand.

The agreement will grant 1933 Industries the license to the DNA brand for the production and sale of hemp-derived CBD products - signaling DNA's first entry into the cannabidiol market - while DNA will leverage 1933's vast distribution network of over 800 retail outlets throughout the US.

Shares of 1933 were up 2.6% in Canada at C\$0.20 and were trading at US\$0.15 over the counter.

Extraction firm Valens Growworks Corp (CVE:VGW) (OTCMKTS:VGWCF) said Thursday that it has struck an amended manufacturing and sales licence agreement with S?RSE Technology Corporation, which granted it an exclusive licence for Canada, Europe, Australia and Mexico to use the proprietary S?RSE emulsion technology to produce, sell and distribute cannabis-infused products.

Valens nudged 0.7% higher in Canada at C\$2.93 and 1% higher over the counter at US\$2.23.

### Duds

Emerald Health Therapeutics Inc (CVE:EMH) (OTCMKTS:EMHTF) was trading 3.6% lower in Canada at C\$0.27 and 5.8% lower over the counter on Thursday morning. The Vancouver-based company's latest financials were disappointing, with the firm posting a C\$17.5 million net loss on the back of a nearly C\$3 million writedown of assets.

**Price:** 0.425

**Market Cap:** \$89.14 m

### 1 Year Share Price Graph



### Share Information

**Code:** MMEN

**Listing:** CSE

52 week	High	Low
	4.69	0.37

**Sector:** Cannabis

**Website:** medmen.com

### Company Synopsis:

*We started MedMen with a simple vision; cannabis as a consumer product. It is a simple idea with profound consequences for how marijuana is cultivated, produced and marketed. Quality standards matter, best practices matter, brand reputation matters. Today, MedMen is the most dominant cannabis enterprise in the emerging legal marijuana industry.*

action@proactiveinvestors.com

Also lower was Aleafia Health Inc (TSE:ALEF) (OTCMKTS:ALEAF), which announced two days ago that it had partnered with a Toronto-based college to provide cannabis education programming. Shares of Aleafia were down 1.6% in Toronto at C\$0.63 but higher on the OTC Pink market at US\$0.48.

Contact Angela at [angela@proactiveinvestors.com](mailto:angela@proactiveinvestors.com)

Follow her on Twitter @AHarmantas

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 [action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

### No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.